University Chemistry ›› 2022, Vol. 37 ›› Issue (9): 2206066.doi: 10.3866/PKU.DXHX202206066

Special Issue: 化学科普(2022)

• Science Education • Previous Articles     Next Articles

Renaissance of Gemtuzumab Ozogamicin

Yi Wu1, Rui Liu1,*(), Yi Lv2   

  1. 1 College of Chemistry, Sichuan University, Chengdu 610064, China
    2 Analytical & Testing Center, Sichuan University, Chengdu 610064, China
  • Received:2022-06-20 Accepted:2022-09-16 Published:2022-09-16
  • Contact: Rui Liu E-mail:liur@scu.edu.cn

Abstract:

This study describes the history of the development of antibody-drug conjugate in the form of interviews. The recognized history of the first commercially available antibody-drug conjugate "getuzumab" was used as the open line, whereas the progress of targeted drugs in chemical molecular design and analysis and detection was used as the dark line. The chemical structure, design, analysis, and development prospects of antibody-drug conjugates were comprehensively introduced.

Key words: Antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (Mylotarg), Targeted therapy, Antibody drug ratio (DAR), Size exclusion chromatography (SEC), Hydrophobic interaction chromatography (HIC)

MSC2000: 

  • G64